Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells.
Our recent studies have revealed that estrogens stimulate an autocrine mechanism determining Leydig tumor cell proliferation. Estrogen overproduction is due to an elevated steroidogenic factor-1 (SF-1) expression and cAMP-response element-binding protein (CREB) phosphorylation, both inducing aromatase overexpression. Although we have shown that increased SF-1 expression depends mainly on higher local insulin-like growth factor I production, the mechanisms and factors determining increased CREB activation in Leydig tumor cells are not completely understood. In this study, we investigated the role of cyclooxygenase-2 (COX-2) in CREB dependent-aromatase expression in Leydig tumor cells. We found that COX-2 is expressed in rat and human Leydigiomas as well as in the rat Leydig tumor cell line R2C, but not in normal testis. Our data indicate that in R2C cells the COX-2-derived prostaglandin E2 (PGE2) binds the PGE2 receptor EP4 and activates protein kinase A (PKA) and ultimately CREB. Inhibitors for COX-2 (NS398), EP4 (AH23848), and PKA (H89) decreased aromatase expression and activity as a consequence of a decreased phosphorylated CREB recruitment to the PII promoter of the aromatase gene. The COX-2/PGE2/PKA pathway also seems to be involved in aromatase post-translational activation, an observation that requires further studies. The reduction in aromatase activity was responsible for a drop in estrogen production and subsequent reduction in cyclin E expression resulting in a decrease in tumor Leydig cell proliferation. Furthermore, COX-2 silencing caused a significant decrease in CREB phosphorylation, aromatase expression, and R2C cell proliferation. These novel findings clarify the mechanisms involved in the growth of Leydig cell tumors and should be taken into account in determining new therapeutic approaches.
Sirianni
Rosa
R
Department of Pharmaco-Biology, University of Calabria, 87036 Arcavacata di Rende (CS), Italy.
Chimento
Adele
A
De Luca
Arianna
A
Zolea
Fabiana
F
Carpino
Amalia
A
Rago
Vittoria
V
Maggiolini
Marcello
M
Andò
Sebastiano
S
Pezzi
Vincenzo
V
D000328:Adult; D000818:Animals; D001141:Aromatase / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D017362:Cyclic AMP Response Element-Binding Protein / Q000737:chemistry; D051546:Cyclooxygenase 2 / Q000737:chemistry* / Q000235:genetics; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007985:Leydig Cells; D008297:Male; D010766:Phosphorylation; D051381:Rats; D011916:Rats, Inbred F344
D017362:Cyclic AMP Response Element-Binding Protein; D016861:Cyclooxygenase Inhibitors; D007334:Insulin-Like Growth Factor I; D001141:Aromatase; D051546:Cyclooxygenase 2
Cancer Res. 2002 Feb 1;62(3):632-5
11830510
Br J Pharmacol. 2000 Aug;130(8):1919-26
10952683
Genome Biol. 2004;5(9):241
15345041
Cancer Res. 2007 Sep 1;67(17):8368-77
17804753
J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):265-74
14623520
Cancer Res. 1998 Sep 1;58(17):3761-4
9731479
Mol Endocrinol. 2004 Aug;18(8):1929-40
15155786
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15072-7
12397176
J Clin Endocrinol Metab. 2005 May;90(5):2563-70
15687328
Biochem Pharmacol. 1995 Nov 9;50(10):1731-3
7503778
Hepatology. 1999 Mar;29(3):688-96
10051469
Biochim Biophys Acta. 1991 Apr 24;1083(1):1-17
1903304
Biol Reprod. 2007 May;76(5):759-68
17251525
J Steroid Biochem Mol Biol. 1997 Sep-Oct;63(1-3):37-44
9449204
Endocr Rev. 1994 Jun;15(3):342-55
8076586
J Biol Chem. 2001 May 25;276(21):18563-9
11278747
Cancer Res. 1985 Jun;45(6):2900-6
3986816
J Surg Oncol. 2007 Oct 1;96(5):424-8
17657731
J Immunol. 2000 Jan 1;164(1):361-70
10605031
Eur J Cancer. 2003 Sep;39(14):2043-9
12957459
Endocrinology. 1998 Dec;139(12):5082-93
9832447
Eur J Endocrinol. 2007 Aug;157(2):239-44
17656605
Gynecol Oncol. 2006 Nov;103(2):425-30
16677697
Oncol Rep. 2000 Nov-Dec;7(6):1377-81
11032948
Annu Rev Pharmacol Toxicol. 2001;41:661-90
11264472
Cancer Res. 1995 Sep 1;55(17):3785-9
7641194
J Exp Clin Cancer Res. 2001 Mar;20(1):117-29
11370818
J Biol Chem. 2002 Dec 27;277(52):50768-75
12372818
Mol Cell Endocrinol. 2007 Jan 2;260-262:244-8
17055151
Endocrinology. 2007 Feb;148(2):735-42
17068133
J Exp Zool. 2002 Jun 15;293(1):73-80
12115921
Endocrinology. 1996 Dec;137(12):5739-42
8940410
Endocrinology. 2004 May;145(5):2186-96
14736734
Prostaglandins Other Lipid Mediat. 2006 Oct;81(1-2):55-70
16997132
J Endocrinol. 2007 Sep;194(3):595-602
17761898
N Engl J Med. 2006 Aug 31;355(9):873-84
16943400
Cancer Res. 1999 Mar 1;59(5):987-90
10070951
Annu Rev Physiol. 2002;64:93-127
11826265
J Biol Chem. 2001 May 25;276(21):18075-81
11278548
J Clin Endocrinol Metab. 1996 Nov;81(11):3843-9
8923826
Cancer Res. 1991 Apr 15;51(8):2047-50
1849040
Cancer Res. 1997 Apr 1;57(7):1276-80
9102213
Adv Prostaglandin Thromboxane Leukot Res. 1995;23:283-5
7732854
J Natl Cancer Inst. 1998 Mar 18;90(6):455-60
9521170
J Gerontol. 1977 May;32(3):258-78
66246
Steroids. 2008 Jan;73(1):104-11
18045633
J Steroid Biochem. 1984 Jan;20(1):161-73
6323862
Cancer Res. 1999 Jan 1;59(1):198-204
9892207
J Clin Endocrinol Metab. 2003 Jun;88(6):2810-6
12788892
J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):175-84
9365188
Biol Reprod. 2005 Aug;73(2):244-55
15814901
Oncol Nurs Forum. 1996 Sep;23(8):1203-11; quiz 1212-3
8883069
J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):367-79
14623533
Methods Enzymol. 1991;206:477-83
1784232
Am J Pathol. 2000 Jan;156(1):347-53
10623684
Eur J Neurosci. 2003 Apr;17(8):1591-606
12752377
Cancer Lett. 1999 Jun 1;140(1-2):27-35
10403538
J Endocrinol. 1999 May;161(2):231-6
10320820
Endocr Rev. 2001 Jun;22(3):289-318
11399746
Mol Endocrinol. 1997 Mar;11(3):292-304
9058376
Cell Signal. 2008 Jun;20(6):1134-41
18374541